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Steroids in Henoch-Schonlein
purpura and abdominal pain
We read with interest the article ‘‘Should
children with Henoch-Schonlein purpura and
abdominal pain be treated with steroids?’’ by
Haroon.1 Considering the low incidence of
Henoch-Schonlein purpura (HSP) in children
(20.4 per 100 000 children in the United
Kingdom, and 12.9 per 100 000 children in
Taiwan),2 3 a randomised controlled trial in a
large cohort would be difficult to conduct.
Haroon1 reported that previous case reports
and retrospective analyses showed an
improvement in pain when steroids are given
to patients with HSP and abdominal pain.
Severe abdominal pain has also been
reported to be associated with the renal
involvement of HSP. Steroids may reduce
abdominal pain in children with HSP, but
there has been no report on the preventive
effect of steroids on the renal involvement in
HSP children with severe abdominal pain.
Furthermore, a recent prospective, rando-
mised, double blind, placebo controlled study
by Huber and colleagues4 showed that early
prednisone therapy did not reduce the risk of
renal involvement or gastrointestinal compli-
cations at 1 year when 21 patients who
received oral prednisone for two weeks were
compared with 19 patients who received
placebo, although the number of study
population is small. In some cases, severe
abdominal pain is poorly controlled by oral
prednisone and may require methylpredniso-
lone pulse therapy.5 Therefore, the use of
steroids should be performed according to the
characteristics of an individual patient with
HSP and a large cohort study should be
performed to elucidate the role of steroids in
HSP children with abdominal pain.
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Dapsone therapy for Henoch-
Schonlein purpura
We read with interest the article ‘‘Dapsone
therapy for Henoch-Schonlein purpura: a
case series’’ by Iqbal and Evans.1 They
reported the clinical course of eight children
with Henoch-Schonlein purpura (HSP) trea-
ted with dapsone due to the severity or
persistence of their symptoms. All gained
clinical response from treatment, but six
relapsed after treatment was stopped, and
nephritis was observed in five patients. They
suggested that dapsone could control cuta-
neous vasculitis rather than cure it. Recently,
persistent purpura has been reported to be
associated with the renal involvement of
HSP.2 Rigante et al reported that relapsing
disease was also significantly related to
persistent purpura, but they could not
explain the association between renal invol-
vement and relapse.3 We reported that
patients with relapse had higher trend for
developing nephritis.4 Nevertheless, Iqbal and
Evans1 could not show a beneficial effect of
dapsone on renal disease, which might be a
limitation of this drug, although it might
suppress the generation of toxic free radicals
in neutrophils and synthesis of IgG and IgA
antibodies.
We have also used dapsone in 15 children
(age 2.7–11.2 years; 12 boys, 3 girls) with
HSP during the past 10 years and obtained a
similar response to the results of Iqbal and
Evans.1 There was a positive effect of dapsone
on the skin rash, but six children relapsed
and five developed nephritis. Therefore, the
use of dapsone should be reevaluated in
children with HSP; although it can control
cutaneous vasculitis, it has no positive effect
on relapse or nephritis, which determine the
prognosis of HSP.
J I Shin, J S Lee, K S Chung
Department of Paediatrics, Yonsei University College
of Medicine, Seoul, Korea;
jsyonse@yumc.yonsei.ac.kr
References
1 Iqbal H, Evans A. Dapsone therapy for Henoch-
Schonlein purpura: a case series. Arch Dis Child
2005;90:985–6.
2 Sano H, Izumida M, Shimizu H, et al. Risk factors
of renal involvement and significant proteinuria in
Henoch-Schonlein purpura. Eur J Pediatr
2002;161:196–201.
3 Rigante D, Candelli M, Federico G, et al.
Predictive factors of renal involvement or
relapsing disease in children with Henoch-
Schonlein purpura. Rheumatol Int 2005;25:45–8.
4 Kim BH, Shin JI, Park JM, et al. Predictive factors
for renal involvement in children with Henoch-
Schonlein purpura. Pediatr Nephrol
2004;19:C158.
Inflicted head injury in infants:
issues arising from the Geddes
hypothesis
Richards and colleagues1 are to be com-
mended for condensing the essence of the
complex issues argued before the Court of
Appeal last year, and for making eminently
sensible suggestions for the role of doctors in
the future. However, there are some matters
that are a proper cause for concern that
remain to be addressed.
Firstly, there is the manner in which
contentious medical hypotheses are put
before the lay public. No person who has
ever spoken to the Press will be unaware of
the fact that he/she has no control over what
subsequently appears in print or over the
airwaves. Whereas one might wish that the
Press would ask the question ‘‘Is this good
science?’’, before launching into headlines
such as ‘‘Gentle shaking ‘may kill babies’’’,2
‘‘Gentle shaking can cause fatal brain
damage in babies, research shows’’,3 and
‘‘Even mild shaking ‘puts baby at risk’:
research could aid appeals against child
killing convictions’’,4 the prudently astute
doctor will appreciate that the prime objective
of a news editor is to sell his story. If, as has
been asserted, learned articles contain the
basis of a hypothesis merely ‘‘meant to
stimulate debate’’,5 then the authors of those
articles must surely have a duty to correct any
recital of their work that puts it higher than
they had intended.
Secondly, the three papers that constituted
the ‘‘unified hypothesis’’ raise questions as to
the quality of the peer review process to
which they were subjected prior to publica-
tion. In particular, as pointed out elsewhere,6
the second of these papers contained a
statement that could not be supported by
the data, namely ‘‘… it may not be necessary
to shake an infant very violently to produce
stretch injury to its neuraxis’’. It is remark-
able that such an unfounded assertion,
carrying powerful implications, was per-
mitted to go forward in a distinguished
scientific journal. It would be of interest to
learn whether the first two papers were
reviewed prior to publication by any practi-
tioner who had clinical care of babies and
infants in life. As to the third paper, it should
have been apparent to the reviewers that the
viability of the ‘‘unified hypothesis’’ espoused
therein was dependent on the credibility of
the assertions made in the first two papers,
yet even at this point, by which time there
was open controversy, the matter went
apparently unchallenged.
Thirdly, it is noted that despite frequent
challenges to the scientific validity of the
‘‘unified hypothesis’’ from most of the
relevant disciplines, in scientific and in
medico-legal fora, it was not until the matter
came before the Court of Appeal that there
was any hint of an acknowledgement that
the hypothesis was flawed. The reliance that
was being placed on their publications can
hardly have escaped the notice of the authors
of the hypothesis. Notwithstanding the
representation made to the Court of Appeal
by the lead author that she ‘‘would be very
unhappy to think that cases were being
thrown out on the basis that my theory was
fact’’,5 the practical effect of the papers was to
introduce a suggestion of reasonable doubt in
an unknown number of cases in criminal and
civil proceedings, as must have been known
to the authors over a number of years. Yet
where in a scientific journal, are we to read a
glimmer of doubt, let alone a retraction, prior
to the Court of Appeal hearing? Or how long
the authors had had it in contemplation that
their hypothesis was wrong? It is difficult to
accept that no such inkling had arisen until
the hearing. It is a sad day for medical science
if mature reflection that leads to an amended
view only comes to light under the rigours of
cross-examination.
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